← Leaderboards
Peter Alexander Forsyth
H. Lee Moffitt Cancer Ctr & Res Inst
$534,316
Attributed
$1,068,631
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $657.1K · FY2017–25$1M$750K$500K$250K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,068,631 · 2
By mechanism
R01$657,121 · 1
R21$411,510 · 1
Top collaborators
- Keiran Smalley2 shared
- Brian Joseph Czerniecki1 shared
Most similar at H. Lee Moffitt Cancer Ctr & Res Inst
Same institution · by research overlap
- Keiran Smalley$7,060,803
- Shari Pilon-Thomas$5,168,533
- Subir Biswas$214,665
- Emmanuel E Zervos$484,571
- Inna Smalley$1,373,060
Others in their field
Other Emerging Leaders on “Tumor”
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Lynn Briscoe · Leidos Biomedical Research, Inc.$120,794,323
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$105,180,681
- Leonard Freedmand · Leidos Biomedical Research, Inc.$78,762,245
- Connie Suders · Leidos Biomedical Research, Inc.$67,882,919
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
Research focus
TumorEffective TherapyImmunotherapySpecimenCellsLeptomeningesCohortGeneticPathway InteractionsResponseCerebrospinal FluidBiologyMouse ModelBrainClinically RelevantClinical TrialsCombined Modality TherapyBraf GeneAntitumor EffectB-LymphocytesBloodAntibody-Dependent Cell CytotoxicityAdoptive TransferCellular Immunotherapy
Grant awards (3)
Remodeling the Immune Landscape in Breast Cancer Leptomeningeal Disease Using Dendritic Cell Therapy is an Effective Treatment and Protects Against Disease Recurrence.$657,121
R01 · FY2025 · CA · contact PI
Using Single Cell Analysis to identify therapeutic vulnerabilities in leptomeningeal melanoma metastases$224,460
R21 · FY2018 · CA
Using Single Cell Analysis to identify therapeutic vulnerabilities in leptomeningeal melanoma metastases$187,050
R21 · FY2017 · CA